These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33393598)

  • 1. US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).
    Naseer S; Weinstein EA; Rubin DB; Suvarna K; Wei X; Higgins K; Goodwin A; Jang SH; Iarikov D; Farley J; Nambiar S
    Clin Infect Dis; 2021 Jun; 72(12):e1103-e1111. PubMed ID: 33393598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Syed YY
    Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
    Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
    J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.
    Silva JT; López-Medrano F
    Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):41-43. PubMed ID: 34598424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
    Echols R; Ariyasu M; Nagata TD
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S559-S564. PubMed ID: 31724048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.
    Paterson DL; Kinoshita M; Baba T; Echols R; Portsmouth S
    Infect Dis Ther; 2022 Apr; 11(2):853-870. PubMed ID: 35184255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
    Ong'uti S; Czech M; Robilotti E; Holubar M
    Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
    Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S
    Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefiderocol to treat complicated urinary tract infection.
    McCarthy MW
    Drugs Today (Barc); 2020 Mar; 56(3):177-184. PubMed ID: 32282864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.
    Drwiega EN; Griffith NC; Danziger LH
    Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
    Timsit JF; Paul M; Shields RK; Echols R; Baba T; Yamano Y; Portsmouth S
    Clin Infect Dis; 2022 Sep; 75(6):1081-1084. PubMed ID: 35148378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.